Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Quarterly Sales
MedTech
J&J MedTech growth slows again as Abiomed weighs on results
J&J’s MedTech unit posted 3.6% operational growth in Q2, reaching $8.93 billion, as weaker Abiomed sales weighed on performance.
Ben Adams
Jul 15, 2026 9:57am
Fierce Pharma
Astellas lifts forecast as Vyloy surge counters trial miss
Feb 5, 2026 11:00am
Fierce Pharma
Sarepta, despite key trial flop, will seek full nod for DMD meds
Nov 4, 2025 7:56am
WuXi AppTec posts sales decline but picks up new business in Q3
Oct 29, 2024 8:25am
Abbott clings to billion-dollar COVID test sales a little longer
Jul 20, 2022 11:37am
Dexcom keeps up the pace as it plots global CGM launches
Apr 29, 2022 11:47am
